A) Structures of USP7 and USP8 screening hits prompted further screening of a spiro indolinone expansion set leading to the identification of new USP7 and USP8 hits for validation studies.
B) Structures of screening hits for each corresponding DUB that were selected for validation studies.
C) Dose-response data for screening hits in Fig 4A and 4B. Compounds were screened in a 12-point dose-response using a kinetic Ub-Rho biochemical assay. Data are represented as mean ± SEM, n ≥ 2.